Information Provided By:
Fly News Breaks for November 2, 2017
TEVA
Nov 2, 2017 | 09:26 EDT
Cowen analyst Ken Cacciatore said investors should continue to avoid Teva shares. The analyst said more cost cuts are needed and 2018 will be very difficult and could become worse depending on if an additional generic of Copaxone launches. He continues to believe that downside exists. Cacciatore maintained his Market Perform rating and $18 price target on Teva shares.
News For TEVA From the Last 2 Days
There are no results for your query TEVA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.